Plain-English translation of NCT06069505 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing a new blood test that can quickly detect whether a serious fungal infection called invasive aspergillosis is resistant to voriconazole, a common antifungal medication. Right now, doctors have to wait for slow fungal cultures to see if the treatment will work. This blood test could provide answers much faster, helping doctors switch treatments quickly if needed.
When invasive aspergillosis becomes resistant to standard antifungal treatment, patients face much higher risks of serious complications or death. The problem is especially common in certain parts of Europe. By detecting resistance quickly through a simple blood test, doctors could start more effective treatments sooner and improve patient outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would provide a blood sample as part of your standard medical care. The researchers will extract DNA from your blood to test for genetic markers that indicate resistance to antifungal medications. This is an observational study, meaning you are not taking a new medication — the research team is simply analyzing your existing samples to develop and improve this diagnostic blood test.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Netherlands
Bart Rijnders
Enrollment target
~300 participants
Started
July 2017
Primary completion
December 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bart Rijnders, MD, PhD
Bart Rijnders
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.